Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Neo-endocrinochemotherapy: a novel approach for enhancing chemotherapeutic efficacy in clinic?

Huang J, Ji G, Xing L, Li H, Wang Z, Ren G, Wu K, Kong L.

Med Hypotheses. 2013 Apr;80(4):441-6. doi: 10.1016/j.mehy.2012.12.037. Epub 2013 Jan 31.

PMID:
23375412
2.

Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine.

Huang J, Jin L, Ji G, Xing L, Xu C, Xiong X, Li H, Wu K, Ren G, Kong L.

BMC Cancer. 2013 Jul 6;13:334. doi: 10.1186/1471-2407-13-334.

3.

New hormonal approaches to the treatment of breast cancer.

Hamm JT, Allegra JC.

Crit Rev Oncol Hematol. 1991;11(1):29-41. Review.

PMID:
1652976
5.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
6.

Sensitive detection of the endocrine effects of the estrogen analogue ethinylestradiol using a modified enhanced subacute rat study protocol (OECD Test Guideline no. 407).

Andrews P, Freyberger A, Hartmann E, Eiben R, Loof I, Schmidt U, Temerowski M, Folkerts A, Stahl B, Kayser M.

Arch Toxicol. 2002 May;76(4):194-202. Epub 2002 Apr 4.

PMID:
12029382
7.
8.

Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.

Drevs J, Fakler J, Eisele S, Medinger M, Bing G, Esser N, Marmé D, Unger C.

Anticancer Res. 2004 May-Jun;24(3a):1759-63.

9.

Cytometry of cyclin proteins.

Darzynkiewicz Z, Gong J, Juan G, Ardelt B, Traganos F.

Cytometry. 1996 Sep 1;25(1):1-13. Review.

10.

Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors.

Spugnini EP, Baldi A, Buglioni S, Carocci F, de Bazzichini GM, Betti G, Pantaleo I, Menicagli F, Citro G, Fais S.

J Transl Med. 2011 Dec 28;9:221. doi: 10.1186/1479-5876-9-221.

11.

Berberine, a genotoxic alkaloid, induces ATM-Chk1 mediated G2 arrest in prostate cancer cells.

Wang Y, Liu Q, Liu Z, Li B, Sun Z, Zhou H, Zhang X, Gong Y, Shao C.

Mutat Res. 2012 Jun 1;734(1-2):20-9. doi: 10.1016/j.mrfmmm.2012.04.005. Epub 2012 Apr 26.

PMID:
22561209
12.

[Tumor dormancy therapy--what do you think of this therapy?].

Sasaki T.

Gan To Kagaku Ryoho. 2001 Dec;28(13):1949-54. Review. Japanese.

PMID:
11791373
13.

Prestimulation of head and neck cancer cells with growth factors enhances treatment efficacy.

Hambek M, Werner C, Baghi M, Gstöttner W, Knecht R.

Anticancer Res. 2006 Mar-Apr;26(2A):1091-5.

14.

Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.

Matsuhashi A, Ohno T, Kimura M, Hara A, Saio M, Nagano A, Kawai G, Saitou M, Takigami I, Yamada K, Okano Y, Shimizu K.

Curr Cancer Drug Targets. 2012 Jul;12(6):625-39.

PMID:
22463590
15.

Novel small molecule cyclin-dependent kinases modulators in human clinical trials.

Senderowicz AM.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S84-95. Review.

PMID:
14508085
16.

Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells.

Croix BS, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS.

J Natl Cancer Inst. 1996 Sep 18;88(18):1285-96.

PMID:
8797768
17.

A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.

Cohen SM, Mukerji R, Timmermann BN, Samadi AK, Cohen MS.

Am J Surg. 2012 Dec;204(6):895-900; discussion 900-1. doi: 10.1016/j.amjsurg.2012.07.027.

PMID:
23231932
18.

A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo.

Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X.

Mol Cancer Ther. 2012 Aug;11(8):1672-82. doi: 10.1158/1535-7163.MCT-12-0131. Epub 2012 Jun 11.

19.

[Late toxicity after chemotherapy of malignant testicular tumors].

Jakob A, Kollmannsberger C, Kanz L, Bokemeyer C.

Urologe A. 1998 Nov;37(6):635-47. Review. German.

PMID:
9887493
20.

Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.

Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S.

Int J Oncol. 2007 May;30(5):1181-8.

PMID:
17390020

Supplemental Content

Support Center